Unmodified Versus Leuko-reduced Allogeneic Red Blood Cells Transfusion in Cancer Patients

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description revisedv2
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
There is evidence to suggest that red blood cell concentrate (RBC) transfusion may have immunomodulatory effects. The aim of this randomized single-center trial is to compare immune responses in patients undergoing cancer surgery and given either an unmodified RBC (UN-RBC) or a leuko-reduced RBC (LR-RBC) transfusion perioperatively.
Trial Details
NCT Number NCT00180869
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions
(from sponsor)		 Cancer, Surgery
Related terms Neoplasms
Enrollment 150 participants
Start Date
Updated on ClinicalTrials.gov